Green is a magic color. Whether we actually see green or not is up to debate. Scientists will tell you know you don't. I have always had a hard time believing this but apparently an orange is not orange we interpret that.
In stock picking green is always good but do we always see it? That's what GBA is here for. We peek under the covers and reveal ideas that others do not see. For GBA the Orange IS Orange all of the time.
In prior threads recently I have gone overboard. In fact my " handlers " are concerned.
I have too many stocks. If the market were to correct 20% I would be in big trouble.
So in this thread I will be handling things a bit differently.- Gone Are The Gummies! Well not completely gone but I will aim to have stock picks that double in a reasonable amount of time, I will cut back on my 1 and 2 week ideas which can flame out and require tight controls.
So perhaps fewer in number but hopefully the same great gains. I usually take you all through my thinking process which requires following a name usually for two weeks before buying and I assemble watch lists because this is how I've always done it. Momentum is important-- you have to " feel " others are watching your idea. That's the rub with stocks-- you can have the greatest idea ever-- a Tennis bag that holds beer and shoots you automatically balls to hit-- but if nobody else knows about it it's like farting in the wind.
You would think I would come on here with a list of ideas and be ready to go. I have no list and am not ready. However I must stop the other ongoing thread, if it hits 1000 pages all of Baron's software is going to implode.
So I come here nearly naked, an average man, ready to take on the big bad market one day at a time. My ally here you all know as VAN. GBA would be nothing without Van. Van is the one who keeps reality in the building. Van is a ying to my yang and if I can get an idea past Van I know it's a good one. Sometimes Van will seem angry-- this is when he is actually THE SENTRY. A superhero that few know about. When I hit a hot streak I become THE SAVANT. Another low end superhero.
Together THE SENTRY & THE SAVANT will give you the stock ride of your lifetime.
Let's Begin.)
<<<<<<GBA Presents: THE GREEN MARKET>>>>>>
Zymeworks price target lowered to $44 from $55 at H.C. Wainwright 08/05 ZYME H.C. Wainwright analyst Robert Burns lowered the firm's price target on Zymeworks to $44 from $55 and reiterates a Buy rating on the shares. The analyst cites projected dilution post the Q2 results for the target drop.
A " projected dilution " that did not come (yet)
ZYME is down quite a bit. They have two lead candidates and there was some shade thrown at one of them and the stk dropped. Part of the problem was the size of the study deemed too small.
Back in July there was a rumored take out speculation:
Zymeworks up 9% as blog report speculates on takeover interest 07/01 ZYME Zymeworks has jumped in afternoon trading after a blog report from Street Insider, citing a source, claimed that the company received a takeover approach and is working with a bank to field other potential interest. The report claims that the "initial bid for Zymeworks was said to be around $50 per share. In midday trading, Zymeworks shares are up $3.15, or 9%, to $37.84.
The stk was $37 in July and $32 now...
Today:
1-Buy ZYME @ $33.
Zymeworks data continue to outperform Herceptin, says Raymond James 08:02 ZYME Raymond James analyst David Novak says ESMO abstracts last night provided a preliminary look at the data Zymeworks will be disclosing on September 16 around its Phase 2 study evaluating Zanidatamab plus chemo in first-line HER2+ metastatic gastroesophageal adenocarcinomas. The company has disclosed an overall response rate of 68.2%, "significantly outperforming" the current standard of care of Herceptin plus chemo, Novak tells investors in a research note. The analyst believes efficacy data continue to support Zanidatamab as superior to Herceptin. He keeps a Strong Buy rating on Zymeworks with a $74 price target.
In stock picking green is always good but do we always see it? That's what GBA is here for. We peek under the covers and reveal ideas that others do not see. For GBA the Orange IS Orange all of the time.
In prior threads recently I have gone overboard. In fact my " handlers " are concerned.
I have too many stocks. If the market were to correct 20% I would be in big trouble.
So in this thread I will be handling things a bit differently.- Gone Are The Gummies! Well not completely gone but I will aim to have stock picks that double in a reasonable amount of time, I will cut back on my 1 and 2 week ideas which can flame out and require tight controls.
So perhaps fewer in number but hopefully the same great gains. I usually take you all through my thinking process which requires following a name usually for two weeks before buying and I assemble watch lists because this is how I've always done it. Momentum is important-- you have to " feel " others are watching your idea. That's the rub with stocks-- you can have the greatest idea ever-- a Tennis bag that holds beer and shoots you automatically balls to hit-- but if nobody else knows about it it's like farting in the wind.
You would think I would come on here with a list of ideas and be ready to go. I have no list and am not ready. However I must stop the other ongoing thread, if it hits 1000 pages all of Baron's software is going to implode.
So I come here nearly naked, an average man, ready to take on the big bad market one day at a time. My ally here you all know as VAN. GBA would be nothing without Van. Van is the one who keeps reality in the building. Van is a ying to my yang and if I can get an idea past Van I know it's a good one. Sometimes Van will seem angry-- this is when he is actually THE SENTRY. A superhero that few know about. When I hit a hot streak I become THE SAVANT. Another low end superhero.
Together THE SENTRY & THE SAVANT will give you the stock ride of your lifetime.
Let's Begin.)
<<<<<<GBA Presents: THE GREEN MARKET>>>>>>
Zymeworks price target lowered to $44 from $55 at H.C. Wainwright 08/05 ZYME H.C. Wainwright analyst Robert Burns lowered the firm's price target on Zymeworks to $44 from $55 and reiterates a Buy rating on the shares. The analyst cites projected dilution post the Q2 results for the target drop.
A " projected dilution " that did not come (yet)
ZYME is down quite a bit. They have two lead candidates and there was some shade thrown at one of them and the stk dropped. Part of the problem was the size of the study deemed too small.
Back in July there was a rumored take out speculation:
Zymeworks up 9% as blog report speculates on takeover interest 07/01 ZYME Zymeworks has jumped in afternoon trading after a blog report from Street Insider, citing a source, claimed that the company received a takeover approach and is working with a bank to field other potential interest. The report claims that the "initial bid for Zymeworks was said to be around $50 per share. In midday trading, Zymeworks shares are up $3.15, or 9%, to $37.84.
The stk was $37 in July and $32 now...
Today:
- Zymeworks(NYSE:ZYME)announcesthe publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody, in first-line HER2-expressing Gastroesophageal Adenocarcinoma (GEA).
- Thirty patients had been treated with zanidatamab in combination with standard of care chemotherapy, and 14 patients remained on treatment.
- The confirmed objective response rate was 68.2% and the disease control rate was 90.9% in 22 HER2-positive response-evaluable patients.
Same problem- low amount of patients (30) in trial...
However with a kicker...
- An updated and expanded data set will be presented at the ESMO Annual Congress held September 16-21, 2021.
- Investing is often guessing. I am guessing that A) I can make it to the 21st without the market correcting.
- B) That expanded data could include good news and or a larger test group.
1-Buy ZYME @ $33.
Zymeworks data continue to outperform Herceptin, says Raymond James 08:02 ZYME Raymond James analyst David Novak says ESMO abstracts last night provided a preliminary look at the data Zymeworks will be disclosing on September 16 around its Phase 2 study evaluating Zanidatamab plus chemo in first-line HER2+ metastatic gastroesophageal adenocarcinomas. The company has disclosed an overall response rate of 68.2%, "significantly outperforming" the current standard of care of Herceptin plus chemo, Novak tells investors in a research note. The analyst believes efficacy data continue to support Zanidatamab as superior to Herceptin. He keeps a Strong Buy rating on Zymeworks with a $74 price target.
